| Christina Tove Dunn, MD | |
|
3305 Central Park Village Dr Ste 200, Eagan, MN 55121-7707 | |
| (651) 406-8860 | |
| Not Available |
| Full Name | Christina Tove Dunn |
|---|---|
| Gender | Female |
| Speciality | Pediatric Medicine |
| Experience | 18 Years |
| Location | 3305 Central Park Village Dr Ste 200, Eagan, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265636963 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 19611 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Home Care And Hospice | Minneapolis, MN | Home health agency |
| Fairview Ridges Hospital | Burnsville, MN | Hospital |
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Clinics | 7113830142 | 658 |
News Archive
The science behind the tingling sensation caused by eating a popular Asian spice has been explained by researchers at UCL.
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test, according to a study between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
› Verified 2 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
The science behind the tingling sensation caused by eating a popular Asian spice has been explained by researchers at UCL.
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test, according to a study between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
› Verified 2 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
The science behind the tingling sensation caused by eating a popular Asian spice has been explained by researchers at UCL.
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test, according to a study between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
› Verified 2 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
The science behind the tingling sensation caused by eating a popular Asian spice has been explained by researchers at UCL.
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test, according to a study between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christina Tove Dunn, MD 3305 Central Park Village Dr Ste 200, Eagan, MN 55121-7707 Ph: (651) 406-8860 | Christina Tove Dunn, MD 3305 Central Park Village Dr Ste 200, Eagan, MN 55121-7707 Ph: (651) 406-8860 |
News Archive
The science behind the tingling sensation caused by eating a popular Asian spice has been explained by researchers at UCL.
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test, according to a study between the Department of Physics and Astronomy and the Institute for Biomedical Sciences at Georgia State University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
› Verified 2 days ago
Christine Marie Schmitz, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3305 Central Park Village Dr Ste 200, Eagan, MN 55121 Phone: 651-406-8860 | |
Barbara Jean Bittner, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1110 Yankee Doodle Rd, Eagan, MN 55121 Phone: 651-454-3970 | |
Dr. James W Clark, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1885 Plaza Dr, Eagan, MN 55122 Phone: 952-993-4001 | |
Ann Marie Ferguson, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3305 Central Park Village Dr Ste 200, Eagan, MN 55121 Phone: 651-406-8860 | |
Deirdre Milligan, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3305 Central Park Village Dr, Eagan, MN 55121 Phone: 651-406-8860 | |
Eleanor-irene B Bucu, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1110 Yankee Doodle Rd, Eagan, MN 55121 Phone: 651-454-3970 |